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Levels of C-reactive protein, creatine kinase-muscle  
and aldolase A are suitable biomarkers to detect the risk 
factors for osteoarthritic disorders: A novel  
diagnostic protocol 
 
Abstract 
Background: C-reactive protein (CRP), creatine kinase-muscle (CK-MM) and aldolase A 
(AldoA) levels are predicted to be realistic biomarkers of osteoarthritic disorders (OADs). 
The objective of the study was to evaluate the levels of CRP, CK-MM, and AldoA and 
determine their correlations with risk factors such as inflammation, muscle degeneration, 
and skeletal muscle damage for OADs. 
Methods: Baseline data from 297 patients, average aged 60.17±7.19 years, suffering with 
OADs for 5.75±1.32 years and 315 participants, average aged 58.96±8.63 years, without 
OADs were collected in this cross-sectional study. Separate analyses were performed for 
the participants with and without OAD symptoms confirming with X-ray or MRI. Blood 
CRP, CK-MM, and AldoA levels were estimated. The receiver operating characteristic 
(ROC) curves, their respective 95% confidence intervals (CIs), and significance values 
were compared between participants with and without OADs to identify the risk factors for 
OADs in relation to biomarkers. 
Results: In patients with OADs, who exhibited degenerative changes on musculoskeletal 
joints and risk factors based on the elevated levels of CRP, CK-MM, and AldoA having 
their mean±SD values, 7.22±6.09 mg/L,135.2±78.56 U/L and 8.09±2.15 U/L, respectively. 
Their respective values of areas under the curves (AUC) of ROC curves were 0.76, 0.68 
and 0.91 respectively, of which all exhibited highly significant differences (p<0.0001) 
compared with the control subjects. 
Conclusion: It is concluded from the results that the elevated levels of studied biomarkers 
represent the predictive above-mentioned risk factors during OADs; therefore, monitoring 
CRP, CK-MM and AldoA levels may be an effective diagnostic method confirming with 
radiological imaging. 
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Osteoarthritic disorder (OAD) is a chronic arthropathy characterized by the potential 
loss of joint cartilage as well as bone hypertrophy (osteophyte formation), connective 
tissue damage, pain symptoms, joint effusion, restricted movement of joints, tenderness 
and crepitus in the joints; OAD is also an inflammatory disease (1-5). OADs usually 
develop in the knee, ankle, and hip joints and in spinal vertebrae (6-7). Several diagnostic 
protocols based on radiology, anatomy, biochemistry, and hematologies, among others, 
have already been established (8-12).  
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Numerous biochemical parameters are abnormally 
altered in various tissues, such as blood, cartilage, bones and 
synovial fluid, in male and female adults with osteoarthritis 
(12-19). Generally, serum C-reactive protein (CRP) levels 
are elevated during inflammation (20). Creatine kinase-
muscle (CK-MM) levels are increased due to muscular 
dystrophy, connective tissue damage, etc. (21-22). Aldolase 
A (AldoA) is an enzyme expressed in a variety of tissues, 
with the highest levels in muscle, and serum Aldo.A levels 
are elevated in response to skeletal muscle disease, 
polymyositis, dermatomyositis, muscular dystrophy and 
inflammatory muscle disease (23). Previous studies have 
utilized an individual research approach for different 
diseases (20-22, 24-26) but have not studied in combined 
affected the serum levels of these markers in OADs. 
Serum CRP levels have been documented as a potent 
marker for inflammation during OADs (27). Serum CK-MM 
levels are reported to be a biochemical marker of muscle and 
connective tissue damage (28), and elevated serum AldoA 
levels have been considered a biomarker for skeletal muscle 
damage (29).  However, a combined approach using all of 
these markers to detect risk factors for OADs from control 
and experimental groups has not been attempted. 
The liver secretes CRP into circulation during infection 
and/or injury, subsequently causing inflammation. CRP was 
first discovered by Tillett and Francis (30) and has been 
studied in laboratory and clinical research by other 
researchers (28-30). OADs may progress when levels of 
biochemical markers, such as CRP (< 6 mg/L), exceed 
standard values.  
On the other hand, there is another non-specific 
inflammation marker which is the erythrocyte sedimentation 
rate (ESR), the rate at which red blood cells fall is measured 
in a period of an hour (31). The common method of 
measuring ESR is via Westerngren method or Wintrobe 
method.  The normal range of ESR is <22 mm/hr for men 
and <29 mm/hr for women. There are multiple causes of a 
high ESR test result, which is commonly used to identify the 
inflammation rate during infection, rheumatoid disease, 
anemia, lymphoma, multiple myeloma, pregnancy, temporal 
arteritis, thyroid disease, Waldenstrom macroglobulinemia 
etc. (32) but not in OADs. Levels of serum CK-MM can be 
estimated using the well-established method of measuring 
CK-MM isoforms (33-36); CK-MM is also expressed in 
several muscle damage disorders. The standard concentration 
of CK-MM is <168 U/L. Researchers have also documented 
the procedure for estimating AldoA levels (reference value is 
< 7.6 U/L) in patients with various diseases, such as skeletal 
muscle damage (28, 37-38). 
The author has already established in the previous study 
that the degeneration in the lumber region always affects the 
bilateral knee joints with degenerative changes and the 
phenomenon is always true in reverse (9). Therefore, OADs 
are developed simultaneously in other multiple 
musculoskeletal joints such as bilateral knee joints, lumbar 
spine, hip joints etc. along with painful joint effusion 
(inflammation/swelling), tenderness, crepitus and restricted 
movement in the joints. All the bones and their joints are 
connected with muscles through tendons. Thus, the primary 
cause of joint pain is the damage of connective muscles 
along with inflammation resulting to which there is restricted 
movement of the joints with stiffness and decreased range of 
motion. Moreover, cartilage protects the joints by absorbing 
the pressure and shock created when we move and put stress 
on them. The primary diagnosis of OAD by physical 
examination, of joints is warmness, redness, crepitus, and 
limited range of motion in the joints. After physical 
examination to confirm the OADs on multiple joints, the 
imaging scans such as CT-scan or x-ray or MRI are done to 
produce an image of bones in case of x-rays for multiple 
joints which has limitations of too much radiation in the 
body. Also, restricted to pregnant patients but not identifying 
the quantum of inflammation, muscle degeneration and 
skeletal muscle damage and in case MRI produces images of 
bones, ligaments, cartilage and synovits with some 
limitations such as certain metal objects implanted in the 
body viz namely: pacemakers, prosthetic joints, rods and 
certain tattoos and also restricted to overweight, very tall and 
claustrophobic patients. Moreover, MRI is very costly, and it 
is to be used for multiple joints to identify the damage made 
during OADs.  
There are other common blood tests such as anti-cyclic 
citrullinated peptide (anti-CCP), rheumatoid factors and 
antinuclear antibody (ANA) to diagnose osteoarthritis (OA) 
but these are very costly and time dependent tests, as well as 
do not firmly quantify the damages made in the muscle and 
tissue levels during OADs due to inflammation, muscle 
degeneration, bone erosion, inflammatory muscle disease, 
and skeletal muscle damage causing to develop muscular 
dystrophy. Moreover, the author has already developed a 
unique deranged anatomical measuring protocol to identify 
quantum of damage of muscles and tissues and also 
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established that with the help of another biochemical test 
methods to identify the quantum of damages in bone level 
such as levels of calcium, phosphorus, ratio of calcium-
phosphorus, 25-OH vitamin D, and intact parathyroid 
hormone (iPTH) during OADs (39-41).  Again, the author 
has previously established that the elevated levels of CRP, 
CK-MM and Aldolase A can be normalized during OADs 
with the help of certain specific phytotherapeutic treatment 
protocol (42).  
The present study attempted for the first time to identify 
that biochemical markers namely; CRP, CK-MM and Aldo 
A are the risk factor for OADs. The combination of the 
above-mentioned blood markers for detecting OADs may be 
an exclusive approach because researchers identified the 
disease with single marker only and no one attempted earlier 
with these combinations. Radiological images such as x-ray 
or CT-scan or MRI as the only diagnostic tools for detecting 
OADs in advance stages and not in early progressive stages 
have many limitations and very expensive as well. 
Moreover, for the detection of OADs, many other methods 
may be alternatively adopted such as physical examination, 
serum anti-CCP and ANA, rheumatoid factors, ratio of 
serum calcium to phosphorus, and iPTH for specific area of 
study.  
But through the investigation of the above-mentioned 
biochemical parameters such as CRP, CK-MM and Aldo A 
from the patient’s serum can be identified accurately, the 
quantum of inflammation, muscle degeneration, skeletal 
muscle damage, which are the key predictive factors of 
OADs, quickly and in affordable low cost in the early stage 
of OAD where there is no pain syndrome or discomfort or 
deformities observed in the joints much before focusing in 
the radiological images. Evaluating the data using specific 
statistical tests, including ROC curves analysis. Therefore, 
the present study has portent the novelty concepts for 
diagnosis of OADs into the relevant biomedical categories.  
 
 
Methods 
Recruitment of participants: A total of 1017 participants, 
aged 40 to 80 years old who were treated at OPTM Health 
Care (P) Ltd. Centers in Kolkata, Delhi and Mumbai, India 
from January 2016 to March 2017 were evaluated in this 
study. The study protocol was evaluated and approved by the 
organic phyto therapeutic method (OPTM) Research 
Institute Ethics Committee. The institute is registered with 
the government. An Institutional Review Board-approved 
consent form for the physical examinations, blood sample 
collections and cervical spine, lumbar spine, hip and knee 
joint images (x-rays, CT scan or MRI) required for the study 
was signed by all patients in the first phase of the screening 
procedure. 
Exclusion criteria: Four hundred and five of 1017 
participants were excluded for having other pathological 
conditions that could explain the existing symptoms, such as 
rheumatic diseases, osteochondritis diseases, inter-articular 
fractures, congenital dysplasia, radicular syndrome, joint 
symptoms caused by malignant tumors, Baker’s cyst, Perthes 
disease, Plica syndrome, dermatomyositis and polymyositis 
diseases, iliopectineal or trochanteric bursitis bone and joint 
infectious diseases and ischemic bone necrosis. The 
following additional exclusion criteria were considered: 
patients with multiple drug dependence; a history of cancer, 
including carcinomatosis and granulocytic leukemia; patients 
with cuts, wounds, or any type of chronic skin disease; a 
history of severe neurological diseases; a history of chronic 
liver, kidney and heart diseases; and patients who did not 
agree to a physical evaluation and/or attend weekly follow-
up visits. 
Study design: After evaluating the exclusion criteria, 315 of 
the remaining 612 subjects with no complaints of pain or 
visual inflammation and no signs of OADs in the cervical 
region, lumber region, hip joints, knee joints or any parts of 
the body, as evidenced by x-ray, CT scan or MRI, were 
considered the control subjects. The remaining 297 subjects 
who had OADs in any region, jointly or singly, according to 
the radiological analysis and complained of pain and visual 
inflammation were considered the experimental group. The 
baseline demographic characteristics of all patients are 
presented in table 1. Co-morbidities were also assessed using 
the Charlson co-morbidity index and methods described by 
Katz et al. (43) and Singh et al. (44). 
Statistical analysis: Continuous variables, such as serum 
CRP, CK-MM, and AldoA levels, in the OAD cohort are 
expressed as the mean, standard deviation (SD), and 95% 
CIs of differences and were compared between the 
experimental and control groups using the Mann-Whitney U 
test, as the data do not follow a normal distribution. Non-
parametric receiver operating characteristic (ROC) curve 
analysis was performed to evaluate the accuracy of various 
measurements in predicting the experimental group, as 
indicated by the area under the curve (AUC). The AUCs for 
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CRP, CK-MM, and AldoA were calculated separately. ROC 
curves indicate the relationship between the true positive 
(sensitivity) and false positive (1- specificity) cases and were 
constructed for CRP, CK-MM and AldoA. An AUC of 1 
indicates a unique test with 100% sensitivity and specificity, 
whereas an AUC of less than 50% indicates that the 
diagnostic test is less useful. The statistical software IBM 
SPSS (Version 20) was used for all statistical analysis. An 
alpha level of 5% was established i.e., a p-value less than 
0.05 was considered statistically significant. 
Evaluation of specific biochemical parameters in blood:  
A 5-ml blood sample was collected in a plain vial from each 
subject with or without OADs. Blood samples were then 
centrifuged at 1000×g for 10 min at 4
o 
C to obtain serum. 
Finally, the serum was used to analyze CRP, CK-MM, and 
AldoA levels in both experimental and control subjects. The 
biomarkers were rigorously analyzed. Each test for each 
experimental and control subject has been rechecked by the 
BS-240 Mindray fully automated biochemistry analyzer 
before reporting the final test result.  
CRP levels (mg/L) were quantitatively assessed using a 
CRP LEIT kit and the latex-enhanced turbidimetric immune 
assay (Agappe Diagnostics Limited, India) at a wavelength 
of 578 nm. The kit was developed based on the methods 
reported by Tillett and Francis (27), Spector and Hart (45) 
and Rifai et al. (46). CK-MM (U/L) levels were 
quantitatively assessed using a Creatine Kinase- MM kit 
(CK-MM/CPK-MM/CK-3) and an immunoassay (Aalto 
Scientific Limited, USA). The kit was developed based on 
the methods reported by Walker (47). AldoA levels (U/L) 
were quantified using an ALDOLASE (ALS) RX MONZA 
AD 189 kit (Randox Laboratories Ltd, Antrim, UK) based 
on a photometric assay at a wavelength of 340 nm. The kit 
was developed according to the method reported by 
Thompson (48). The subjects suffering from OADs with 
inflammation, muscle degeneration and skeletal muscle 
damage were studied to identify a specific biochemical 
parameter, such as CRP, CK-MM, and AldoA levels, in the 
affected population. All blood tests were conducted under 
the supervision of the Chief Biochemist and the Chief 
Pathologist in the Galaxy Medical Centre, an ISO 9001: 
2015 certified lab with Registration No. L/004-(05)-15/0129 
under the W.B Clinical Establishment Act, 1950. 
Evaluations of the mean, standard deviation and 
significance value and the ROC curves analysis: The 
mean, standard deviation, mean difference (MD), 95% 
confidence intervals (CI) and their significance values (p-
values) were evaluated and ROC curves analyses were 
performed for the three biomarkers among 297 subjects with 
OADs and 315 subjects without OADs. While analyzing the 
ROC curves, the sensitivity and specificity for each 
biochemical parameter were calculated and thereafter, the 
accuracy, positive predictive value (PPV) and negative 
predictive value (NPV) were evaluated with the help of 
following formulae: 
Prevalence = (true positive + false negative)/ (true 
positive + false positive +false negative +true negative); 
Accuracy= sensitivity x prevalence + (specificity) x (1-
prevalence); positive predictive value (PPV) = (sensitivity x 
prevalence)/[sensitivity x prevalence + (1-specificity) x(1-
prevalence)]; 
Negative predictive value (NPV) = specificity x (1-
prevalence)/ [(1-sensitivity) x prevalence + specificity x (1-
prevalence)].   
Evaluation of correlation coefficients between two 
biomarkers: To determine the predictive values of the three 
biomarkers in patients with OADs, the correlation 
coefficients between two biomarkers were separately 
evaluated for OAD and non-OAD participants. 
 
 
Results 
A total of 297 patients aged 60.17±7.19 years those who 
were suffering with OAD for 5.75±1.32 years and 315 
patients aged 58.96±8.63 years without OAD symptom 
confirmed by x-ray or MRI.  
Baseline demographic characteristics of all patients for 
both experimental and control groups who were not being 
treated by oral medications; injections; massage with any 
type of herbal gels; and any type of alternative interventions 
or treatments for diminishing pain or inflammation, for 
muscle relaxation, or to improve the skeletal muscles during 
the last four weeks and did not undergo arthrocentesis within 
three months prior to the blood tests are shown in table 1. 
The risk factors and values of the biochemical markers, such 
as CRP, CK-MM, and AldoA were evaluated using the 
serum samples of experimental subjects suffering from 
OADs and control subjects without OADs. 
Table 2 A shows that the mean± SDs of CRP, CK-MM 
and AldoA levels for 297 subjects with OADs and that these 
differences were highly significant (P<0.001). Compared to 
the 315 subjects without OADs.  
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Table 1. Demographic data and baseline characteristics of subjects 
Characteristics Experimental group Control group 
No of subjects 297 315 
Age (yrs), (mean±SD) 60.17 (7.19) 58.96 (8.63) 
BMI (kg/m²) (mean±SD) 29.94 (3.31) 28.42 (3.38) 
Females 193 (65%) 231 (73%) 
Period of suffering (yrs), (mean±SD) 5.75 (1.32) - 
Indian ethnic group (%) 
Bengali 65 (22) 71 (22) 
Gujrati 34 (11) 35 (11) 
Marwaree 41(14) 43 (14) 
Marathi 29(10) 33 (10) 
Tamil 37 (12) 37 (12) 
Punjabi 38 (13) 41 (13) 
Shindhi 29 (10) 31(10) 
North East India 24 (8) 24 (8) 
Food habit (%) 
Vegetarian 181 (61) 205 (64) 
Non - vegetarian 116 (39) 115 (36) 
Analysis of radiological reports (%) 
Unilateral knee OAD* with osteophytes 63 (21) - 
Bilateral knee OAD with osteophytes 55 (19) - 
 OAD changes in cervical vertebrae 39 (13) - 
 OAD changes in lumbar vertebrae  51 (17) - 
Unilateral OAD in hip joint with osteophytes 27 (9) - 
Bilateral OAD in hip joints with osteophytes 28 (10) - 
Unilateral OAD in shoulder joint  23 (8) - 
Bilateral OAD in shoulder joints 11 (3) - 
Unilateral OAD in ankle joint 8(2) - 
Bilateral OAD in ankle joints 7(2) - 
Work status (%) 
Employed fulltime 78 (26) 93 (30) 
Employed part time 21 (7) 25 (8) 
Housewife / Homemaker 72 (24) 83 (26) 
Retired 45 (16) 42 (13) 
Self employed 81 (27) 72 (23) 
Multiple complaints (%) 
Constipation 68 (23) 80 (25) 
Acidity & reflux 72 (24) 45 (14) 
Insomnia 66 (22) 62 (20) 
Varicose vein 34 (11) 32 (10) 
Urinary incontinence 43 (14) 17 (5) 
Crepitus during knee flexion 32 (11) - 
Morning stiffness (<30 minute) 37 (12) - 
Measures taken to diminish pain (%) 
Using knee caps 69 (23) - 
Using a lumbar belt 49 (16) - 
Using a collar belt 35 (12) - 
Using a stick/walker 34 (12) - 
                                 *OAD: Osteoarthritic disorder 
 Caspian J Intern Med 2019; 10(1):25-35 
30                                                                              Ganguly A, et al. 
Table 2A. Statistical analysis of the mean, standard division (SD) and 95% confidence interval (CI) for 297 OAD subjects 
and 315 subjects without OAD 
Biochemical parameters 
Control group Experimental group P-value 
a
MD 95% CI of difference 
Mean (SD) Mean (SD) 
  
Lower Upper 
CRP (mg/L) 3.54 (1.45) 7.22 (6.09) <0.001 -3.68 -4.37 -2.99 
CK-MM (U/L) 91.44 (38.71) 135.22 (78.56) <0.001 -43.78 -53.53 -34.03 
AldoA (U/L) 5.26 (1.21) 8.09 (2.15) <0.001 -2.81 -3.09 -2.53 
a: Mean difference 
 
Table 2B.  Analysis of receiving operating characteristic (ROC) curves for 297 OAD subjects and 315 subjects without OAD 
 
Biochemical parameters 
Receiving operating curve analysis 
Area under the 
curve (AUC) 
p-value 
95% CI of AUC 
Lower Upper 
CRP (mg/L) 0.76 <0.001 0.72 0.80 
CK-MM (U/L) 0.68 <0.001 0.64 0.72 
AldoA (U/L) 0.91 <0.001 0.88 0.93 
 
When analyzing the ROC curves, the optional cutoff 
points were considered as <6, <168 and <7.6 for CRP, CK-
MM and Aldo A respectively. The analyses of ROC curves 
in respect of CRP, CK-MM and Aldo A for 297 OAD  
 
 
subjects and 315 non-OAD subjects with all significant values 
(p<0.001) are shown in table 2B. The analyses of sensitivity, 
specificity, positive predictive value (PPV), negative predictive 
value (NPV) and diagnostic accuracy are shown in the table 3.  
Table 3. Analyses of Sensitivity, Specificity, PPV, NPV and diagnostic accuracy 
Parameter Sensitivity (%) Specificity (%) 
PPV*  
(%) 
NPV*  
(%) 
Diagnostic accuracy  
(%) 
CRP 50.51 98.41 96.77 67.83 75.16 
CK- MM 48.82 78.73 68.40 62.00 64.22 
ALDO A 81.82 89.21 87.73 83.88 85.62 
*PPV: Positive predictive value, NPV: Negative predictive value
The ROC curves for CRP, CK-MM, and AldoA levels 
are depicted in Fig 1.  
The area under the curve (AUC) and 95% CIs of the 
AUC for the CRP, CK-MM and AldoA levels were highly 
significant (P<0.001) in all cases.  
Table 4 shows that the correlation coefficients between 
CRP and CK-MM as well as CRP and AldoA were highly 
significant (P=0.032 and P=0.001), whereas the R-value 
between CK-MM and AldoA was not statistically significant 
(P=0.092) for OAD patients.  
The R-values between CRP and CK-MM as well as CRP 
and AldoA were not significant (P=0.167 and P=0.850), but 
the R-value between CK-MM and AldoA was highly 
significant (P=0.032) for non-OAD subjects. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Receiver operating characteristic curves for C-
reactive protein (CRP), creatine kinase-muscle (CK-MM) and 
aldolase A (AldoA). The area under the curve was 0.761 (95% 
CI = 0.723 – 0.800) for CRP, 0.677 (95% CI = 0.635 – 0.719) for 
CK-MM, and 0.908 (95% CI = 0.883 – 0.932) for AldoA  
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Table 4. Correlation coefficient between two biomarkers 
Biomarkers 
Experimental group Control group 
R-value P-value R-value P-value 
CRP and CK-MM -0.124 0.032 -0.080 0.167 
CRP and AldoA 0.179 0.001 -0.011 0.850 
CK-MM and AldoA 0.097 0.092 0.123 0.032 
 
Discussion 
The reference value for each biochemical parameter in 
adults has been established as <6 mg/L CRP, <168 U/L CK-
MM and <7.6 U/L AldoA. CRP levels increase due to 
inflammation (20, 43-45), CK-MM levels are elevated in 
response to muscular dystrophy, connective tissue damage, 
etc. (21-22; 25), and AldoA levels increase due to skeletal 
muscle damage and bone erosion (23), suggesting that these 
markers may be risk factors for OADs. It is further indicated 
from the results that a significantly increasing trend was 
observed (p<0.001) for each parameter when compared to 
the subjects having OADs with the control subjects 
However, previous studies were conducted in separate 
subjects by several researchers, and no study has attempted 
to correlate the risk factors, such as muscular and skeletal 
muscle damage and inflammation, with OADs. 
Researchers have investigated the relationship between 
AldoA levels in the circulation and levels of the anti-aldolase 
A autoantibody in serum, but no correlation was observed. 
The reactivity of anti-aldolase A autoantibody in the serum 
of patients with rheumatoid arthritis was evaluated using 
denatured and native AldoA, and this autoantibody 
predominantly bound to denature enzyme (23). 
The ROC curve has many advantages in medical and/or 
biological sciences, as it has been reported by many 
researchers (55-60). The analysis of ROC curve is used to 
determine the risk factors based on biomarker data from 
biochemical analysis in the clinic (61).   
In statistical analysis, the probability of a positive test 
result for subjects with OADs is derived from the variation 
of test results among subjects with and without OADs; this 
probability is basically a conditional probability of correctly 
identifying subjects with OADs and is based on the 
sensitivity of the test in detecting the true positive fraction. 
Meanwhile, the probability of negative test results for 
control subjects without disease is the conditional probability 
of correctly identifying subjects without OADs, which is 
based on the specificity of the test for the true negative 
fraction. These indices are very useful for the evaluation of 
biochemical markers (CRP, CK-MM, and AldoA) when data 
are obtained from the laboratory. Positive test results identify 
the risks of developing inflammation, muscular degeneration 
and skeletal muscle damage among patients with OADs, 
whereas negative test results identify the probability of being 
healthy without any risk factors. However, from the 
estimates of these biochemical markers, risk factors of 
OADs and correlations among variables can be identified. 
Nonetheless, these factors are influenced by the prevalence 
of OADs and the risk of other diseases in subjects. The 
statistical analysis of ROC curve is used to detect risk factors 
for OADs in the present study are commonly used by other 
researchers investigating the prevalence of other diseases, 
such as cancer and infectious diseases (61, 65-67). Finally, 
this prediction tool is helpful in determining diagnostic 
accuracy (65, 68). 
 An important finding from the results showed that the 
elevated AldoA levels is a greater risk factor for skeletal 
muscle damage among patients with OADs than the other 
two markers, CRP and CK-MM and the values were highly 
significant (P<0.001) for all markers. The present results 
clearly indicated the presence of inflammation, which was 
confirmed by the CRP test, and confirmed skeletal muscle 
damage, as indicated by the elevated AldoA levels. CK-MM 
levels were also elevated along with the other two 
biomarkers, indicating that muscular degeneration occurred 
in patients with OADs (20, 22-23).  
In general, OADs can be identified only in advance stage 
for assessing the condition of bones at musculoskeletal joints 
such as joint space narrowing, osteophyte formation, 
sclerosis and deformity of bony ends using anterior-posterior 
(AP) views of x-ray images on various musculoskeletal 
joints by four-graded scale developed by Kellgren-Lawrance 
(69)  but definite quantum of  inflammation, muscle 
degeneration and skeletal muscle damage affecting bone and 
cartilage damage of joints cannot be identified from x-ray 
images  whereas, MRI of various musculoskeletal joints can 
also be assessed at advance stage by four graded scale 
known as Fredericton MRI classification scale which 
includes periosteal edema, bone marrow edema visible only 
on T2-weighted image or T1- and T2-weighted images and 
multiple focal /linear areas of intracortical signal 
abnormalities (70) which are  very costly affairs and not 
affordable by common people for various individual joints to 
identify OADs  but not at early progressive stage. Therefore, 
the elevated levels of CRP, CK-MM, and AldoA observed in 
 Caspian J Intern Med 2019; 10(1):25-35 
32                                                                              Ganguly A, et al. 
patients with OADs have confirmed that these biomarkers 
are predictive risk factors that may be monitored and serve 
as one of the best diagnostic protocols quickly and in 
affordable low cost even  in the  early progressive stage  of 
OAD where there is  no  pain syndrome or discomfort or 
deformities observed in the joints  confirmed with x-rays or 
MRI images on various musculoskeletal joints only at 
advance stage but not in early progressive stage. Moreover,  
there are certain  limitations for MRI imaging such as metal 
objects implanted in the body such as pacemakers, prosthetic 
joints, rods and certain tattoos and also restricted to 
overweight, very tall and claustrophobic patients.  
Furthermore, the author has already developed a unique 
deranged anatomical measuring protocol to identify quantum 
of damage of muscles and tissues plus other biomarkers such 
as calcium, phosphorus, and ratio of calcium to phosphorus 
and level of parathyroid hormone to identify the condition of 
damaged bone during OADs (39-42). Again, the author had 
shown earlier that the elevated levels of CRP, CK-MM and 
Aldolase A can be normalized, even at early progressive 
stage of OADs with the help of certain specific 
phytotherapeutic treatment protocol when significant 
improvements are observed in the imaging scans such as x-
ray or MRI or CT-scan (41).  Additionally, the result shows 
the high predictive values of the three biomarkers in patients 
with OADs when the correlation coefficients (R-values) are 
separately calculated between two biomarkers.  
In conclusions based on the present study, elevated levels 
of the biochemical markers such as CRP, CK-MM, and 
AldoA represent the key predictive risks factors such as 
inflammation, muscle degeneration, muscular dystrophy, 
inflammatory muscle disease and skeletal muscle damage 
affecting muscle bone and cartilage damage of various 
musculoskeletal joints; therefore, monitoring serum CRP, 
CK-MM and Aldolase A levels may be a novel approach for 
the quick detection of OADs and in an affordable low cost 
even at early  progressive stage when there is no significant  
pain syndrome or discomfort or deformities observed in the 
x-ray or MRI images (20-23, 43-45)  
Further research has been undertaken to identify cartilage 
damage, to establish diagnostic tools for other OADs, 
specially rheumatoid arthritis, to measure pro- and anti-
inflammatory cytokines such as IL-10, TNF-α, collagen 4-
hydroxyproline (O-Hyp) and hyaluronic acid (synovits) both 
in volume and chemical compositions which are not at all 
possible with the help of either x-ray or MRI imaging. 
Limitation of the study 
The patients suffering from the following disorders are 
restricted to participate in the present study: 
1. Rheumatic diseases;  
2. Osteochondritis diseases; 
3.  Congenital dysplasia;  
4. Radicular syndrome;  
5. Joint symptoms caused by malignant tumors;  
6. Dermatomyositis and polymyositis diseases; 
7. Iliopectineal or trochanteric bursitis;  
8. Ischemic bone necrosis. 
9. Bone and joint infectious diseases 
10. Cuts, wounds or any type of chronic skin and infectious 
diseases; 
11. Parallel multiple drug dependence for concomitant 
diseases or risk conditions requiring drug treatment 
including psychiatric diseases etc. 
12. A history of cancer, including carcinomatosis and 
granulocytic leukemia. 
13. A history of severe neurological diseases. 
14. A history of chronic liver, kidney and heart diseases. 
15. Patients who did not agree to give blood sample may be 
due to drugs/alcohol addiction, pregnancy and such other 
reasons. 
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